MarketCap
Facebook
X
Telegram
Kezar Life Sciences EV - Enterprise Value | KZR
Annual EV - Enterprise Value Kezar Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.9 M | 31.2 M | 4.34 M | 24 M | 742 M | 231 M | 49.4 M | 158 M | 28.9 M | 22.8 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 742 M | -19.9 M | 127 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
3.31 B | $ 93.79 | 6.17 % | $ 6.96 B |  USA |
 |
Lipocine
LPCN
|
15.2 M | $ 1.58 | 3.27 % | $ 8.61 M | USA |
 |
Seres Therapeutics
MCRB
|
110 M | $ 1.97 | -5.74 % | $ 17.5 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
10.3 B | $ 399.41 | -0.17 % | $ 8.96 B | USA |
 |
CEL-SCI Corporation
CVM
|
21.1 M | $ 1.44 | 6.67 % | $ 11.5 M | USA |
 |
Inventiva S.A.
IVA
|
313 M | $ 3.8 | 4.68 % | $ 227 M |  France |
 |
MeiraGTx Holdings plc
MGTX
|
835 M | $ 9.0 | 5.73 % | $ 724 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
837 K | $ 1.93 | 4.89 % | $ 2.53 M | USA |
 |
Eton Pharmaceuticals
ETON
|
599 M | $ 56.44 | 19.7 % | $ 1.52 B | USA |
 |
IDEAYA Biosciences
IDYA
|
2.7 B | $ 31.24 | 1.92 % | $ 2.76 B | USA |
 |
Lantern Pharma
LTRN
|
13.6 M | $ 0.56 | 4.61 % | $ 6.1 M | USA |
 |
Foghorn Therapeutics
FHTX
|
582 M | $ 1.86 | -2.62 % | $ 117 M | USA |
 |
Ocugen
OCGN
|
652 M | $ 0.93 | 13.53 % | $ 291 M | USA |
 |
Oncolytics Biotech
ONCY
|
32.6 M | $ 0.44 | -2.01 % | $ 42.2 M |  Canada |
 |
Minerva Neurosciences
NERV
|
213 M | $ 2.42 | 5.0 % | $ 20.5 M | USA |
 |
Kamada Ltd.
KMDA
|
415 M | $ 7.22 | 5.09 % | $ 416 M |  Israel |
 |
Neurocrine Biosciences
NBIX
|
665 M | $ 164.42 | 2.91 % | $ 16.4 B | USA |
 |
Nanobiotix S.A.
NBTX
|
1.45 T | $ 30.7 | 2.05 % | $ 1.47 T | France |
 |
Mereo BioPharma Group plc
MREO
|
2.03 B | $ 0.28 | 0.93 % | $ 223 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
488 M | $ 7.53 | 7.81 % | $ 1.09 B | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
635 M | $ 1.78 | 10.25 % | $ 646 M | USA |
 |
Moleculin Biotech
MBRX
|
706 K | $ 8.87 | 1.6 % | $ 10.5 M | USA |
 |
Nurix Therapeutics
NRIX
|
1.47 B | $ 15.3 | 3.1 % | $ 1.33 B | USA |
 |
Nkarta
NKTX
|
210 M | $ 1.75 | 11.15 % | $ 129 M | USA |
 |
MacroGenics
MGNX
|
293 M | $ 2.35 | 5.86 % | $ 148 M | USA |
 |
Protagonist Therapeutics
PTGX
|
5.46 B | $ 131.96 | -2.54 % | $ 8.39 B | USA |
|
Nuvation Bio
NUVB
|
2.12 B | $ 4.15 | -0.72 % | $ 1.42 B | USA |
 |
Novo Nordisk A/S
NVO
|
541 B | $ 40.36 | 0.21 % | $ 179 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
6.72 M | $ 0.91 | 0.95 % | $ 13.9 M | USA |
 |
NextCure
NXTC
|
25.3 M | $ 5.55 | 8.61 % | $ 15.8 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
59.5 M | $ 1.25 | -1.57 % | $ 65.7 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
1.45 B | $ 7.32 | 8.21 % | $ 637 M | USA |
 |
Kymera Therapeutics
KYMR
|
7.74 B | $ 132.5 | 3.42 % | $ 11.2 B | USA |
 |
Oragenics
OGEN
|
-888 K | $ 0.35 | 0.29 % | $ 755 K | USA |
 |
Ovid Therapeutics
OVID
|
307 M | $ 2.86 | 10.66 % | $ 372 M | USA |
 |
Passage Bio
PASG
|
10.1 M | $ 3.9 | 12.72 % | $ 12.5 M | USA |
 |
Vaxcyte
PCVX
|
8.52 B | $ 63.86 | 3.13 % | $ 8.69 B | USA |
 |
Relay Therapeutics
RLAY
|
516 M | $ 18.59 | 9.32 % | $ 3.19 B | USA |
 |
Precigen
PGEN
|
1.07 B | $ 4.47 | 5.81 % | $ 1.4 B | USA |
 |
Avidity Biosciences
RNA
|
9.93 B | $ 8.36 | 0.48 % | $ 1.15 B | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
-12.6 M | $ 0.8 | -1.38 % | $ 4.79 M | USA |
 |
Praxis Precision Medicines
PRAX
|
7.01 B | $ 277.94 | 5.85 % | $ 6.25 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
314 M | $ 3.59 | 0.98 % | $ 276 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
133 M | $ 1.36 | 1.88 % | $ 143 M |  Niderland |
 |
Ocular Therapeutix
OCUL
|
1.12 B | $ 6.61 | 2.8 % | $ 1.24 B | USA |
 |
PolyPid Ltd.
PYPD
|
61.3 M | $ 6.08 | 7.23 % | $ 99.4 M | Israel |
 |
Outlook Therapeutics
OTLK
|
104 M | $ 0.44 | -0.93 % | $ 15.3 M | USA |
 |
uniQure N.V.
QURE
|
1.17 B | $ 21.68 | 3.19 % | $ 1.25 B | Niderland |
 |
Ultragenyx Pharmaceutical
RARE
|
3.2 B | $ 15.48 | -0.58 % | $ 1.53 B | USA |
 |
Rafael Holdings
RFL
|
48.1 M | $ 1.02 | -4.67 % | $ 52.4 M | USA |